CAS Number: 68693-11-8 / 112111-47-4
Provigil | 68693-11-8
Provigil (modafinil) is a novel wake-promoting agent approved for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy, offering an alternative to traditional central nervous system stimulants. Long-term, 40-week open-label studies demonstrated that modafinil is effective and well-tolerated, with over 80% of patients showing improved disease severity and significant, sustained improvements in Epworth Sleepiness Scale scores and quality of life, while common adverse events were mild to moderate (e.g., headache, nervousness, nausea). Furthermore, quasi-experimental comparisons in sleep-deprived aviators indicated that modafinil has equivalent efficacy to dextroamphetamine (Dexedrine®) in sustaining performance, mood, and alertness, though modafinil was associated with more spontaneous side effect reports but potentially a lower abuse liability due to fewer euphoriant effects compared to amphetamines.
Product Information
HM Chemical Trading GmbH supplies industrial-grade specialty chemicals and raw materials with reliable international logistics support.
References
-
Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy
Modafinil is effective for the long-term treatment of EDS associated with narcolepsy and significantly improves perceptions of general health. Modafinil is well tolerated, with no evidence of tolerance developing during 40 weeks of treatment.
DOI: 10.1016/S1389-9457(00)00031-9 -
Efficacy of stimulants for fatigue management: the effects of Provigil® and Dexedrine® on sleep-deprived aviators
The present report details the results of a quasi-experimental comparison between the alerting effects of modafinil (Provigil®) and those of dextroamphetamine (Dexedrine®) in sleep-deprived pilots. Data from two separate placebo-controlled studies (one on Dexedrine® and one on Provigil®) were merged and analyzed to determine whether one compound produced greater effects than the other relative to placebo. The results indicated there were differences between the two stimulants on only two of the 14 dependent measures.
DOI: 10.1016/S1369-8478(01)00011-0